Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 10.23 USD -1.35% Market Closed
Market Cap: 265.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 39.95 USD with a low forecast of 22.22 USD and a high forecast of 52.5 USD.

RNAC Lowest Forecast
Wall Street Target
22.22 USD
117% Upside
RNAC Average Forecast
Wall Street Target
39.95 USD
291% Upside
RNAC Highest Forecast
Wall Street Target
52.5 USD
413% Upside
Lowest
Price Target
22.22 USD
117% Upside
Average
Price Target
39.95 USD
291% Upside
Highest
Price Target
52.5 USD
413% Upside
Cartesian Therapeutics Inc Competitors:
Price Targets
IMNM
Immunome Inc
182% Upside
LVTX
LAVA Therapeutics NV
42% Upside
ZYME
Zymeworks Inc
84% Upside
CRNX
Crinetics Pharmaceuticals Inc
147% Upside
IMNM
Immunome Inc
182% Upside
LVTX
LAVA Therapeutics NV
42% Upside
ZYME
Zymeworks Inc
84% Upside
CRNX
Crinetics Pharmaceuticals Inc
147% Upside
FYB
Formycon AG
150% Upside
N
4893
Noile-Immune Biotech Inc
175% Upside
4593
Healios KK
12% Upside
A
397030
AprilBio Co Ltd
110% Upside

Revenue
Forecast

Revenue Estimate
Cartesian Therapeutics Inc

For the last 8 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 22%. The projected CAGR for the next 3 years is -81%.

22%
Past Growth
-81%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
What are analyst estimates?

See Also

Summary
RNAC intrinsic value, competitors valuation, and company profile.
DCF Valuation
RNAC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RNAC stock valuation using valuation multiples.
Wall Street Estimates
RNAC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RNAC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNAC's stock price target?
Price Target
39.95 USD

According to Wall Street analysts, the average 1-year price target for RNAC is 39.95 USD with a low forecast of 22.22 USD and a high forecast of 52.5 USD.

What is Cartesian Therapeutics Inc's Revenue forecast?
Projected CAGR
-81%

For the last 8 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 22%. The projected CAGR for the next 3 years is -81%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.